Organogenesis Holdings

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organogenesis Holdings reports Q4 revenue decline but exceeds guidance

Organogenesis Holdings faced revenue decline in Q4 2022 but exceeded guidance expectations.
Operational progress in clinical trials and a healthy cash position are notable strengths.
Challenges include declining product sales and increased operating expenses.
Strategic investments and growth opportunities in clinical initiatives are key focus areas for 2023.

Organogenesis Holdings reports robust Q1 revenue growth and strategic focus

Organogenesis Holdings delivered strong revenue growth driven by Advanced Wound Care products, while facing challenges with increased expenses and a net loss.
The company's focus on innovation, market expansion, and cost management presents opportunities for sustained growth and competitive positioning.
Navigating regulatory requirements and market dynamics will be crucial for Organogenesis to capitalize on opportunities and mitigate challenges in the upcoming quarters.

Organogenesis Holdings faces revenue challenges amidst strong business trends

Organogenesis Holdings faced revenue challenges due to LCDs impacting products, leading to withdrawn guidance. Despite this, the company maintained a strong gross profit margin and focused on strategic sales shifts. Opportunities for growth exist in product focus and ongoing trials.

Organogenesis reports Q3 revenue decline, eyes growth amid regulatory shifts

Organogenesis Holdings navigated challenges in Q3 2023 with a focus on operational efficiency, financial strength, and strategic growth initiatives for the future.
While facing revenue declines and market uncertainties, the company capitalized on positive regulatory developments and operational advancements to drive performance.
Looking ahead, Organogenesis aims to address challenges, seize growth opportunities, and maintain its competitive edge in the evolving healthcare market landscape.

Organogenesis Holdings reports Q4 revenue decline but anticipates 2024 growth

Organogenesis Holdings faced challenges in Q4 but showed positive momentum and progress in clinical trials. The company expects revenue growth in 2024 and is focusing on customer engagement and new product launches for further expansion.

Organogenesis Holdings beats revenue expectations, eyes FDA approval for ReNu

Organogenesis Holdings demonstrated solid financial performance in Q1, with revenue exceeding expectations and improved operating metrics.
While facing challenges in certain revenue segments, the company's focus on innovation and regulatory progress presents growth opportunities.
Maintaining a strong cash position and reaffirming revenue guidance underscore Organogenesis' resilience and strategic outlook for the future.

Organogenesis Holdings exceeds Q3 revenue guidance, focuses on innovation

Organogenesis Holdings delivered a strong performance in Q3 2024, surpassing revenue guidance and demonstrating solid financial results.
While facing challenges such as potential market disruption and regulatory issues, the company remains focused on strategic initiatives and innovation to drive growth.
With opportunities in Medicare reimbursement, product development, and regulatory milestones, Organogenesis is well-positioned for future success and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

CANTON, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Board of Directors has elected President and Chief Executive Officer Gary S.

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, May 10th.

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023

Transitioning all skin substitutes to ASP-based payments has the potential to substantially reduce Medicare Part B expenditures Transitioning all skin substitutes to ASP-based payments has the potential to substantially reduce Medicare Part B expenditures

Organogenesis Applauds Findings from the Office of Inspector General

Motorcar Parts of America

Unisys

The S&P SmallCap 600 index dropped all three stocks.

Why Shares of Unisys, Organogenesis, and Motorcar Parts of America Fell Today

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2022 Earnings Conference Call March 1, 2023 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen to the Fourth Quarter and Fiscal Year 2022 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports.

Organogenesis Holdings Inc. (ORGO) Q4 2022 Earnings Call Transcript

CANTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022.

Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

CANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today reported the favorable outcome of the interim analysis of its Phase 3 clinical trial for the management of symptoms associated with knee osteoarthritis.

Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2022 financial results will be reported after the market closes on Wednesday, March 1st.

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023

Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-organogenesis-holdings-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Organogenesis Holdings Inc.

CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference, which is being held at The Fontainebleau Miami Beach in Miami, FL on Thursday, December 8th. The conference consists of panel discussions and 1x1 meetings with investors. Management will participate in 1x1 meetings.

Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Corporate Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Ryan Zimmerman - BTIG Operator Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2022 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Organogenesis Holdings Inc. (ORGO) Q3 2022 Earnings Call Transcript

Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates

CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022.

Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results

The market-wide sell-off has uncovered countless investment opportunities in the small and mid-cap healthcare arena. I have rediscovered Organogenesis trading at an incredible discount. Organogenesis has relied on PuraPly to accelerate growth while enjoying a diversified revenue stream from their other marketed products. This has led the company to become net positive.

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2022 financial results will be reported after the market closes on Wednesday, November 9th.

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022

CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 12th-14th. Management will host a fireside chat on Tuesday, September 13th at 11:45 a.m. Eastern Time.

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Wilmington, Delaware--(Newsfile Corp. - August 30, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-organogenesis-holdings-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Organogenesis Holdings Inc

PuraPly MZ is an Innovative Product for Complex Surgical Wounds PuraPly MZ is an Innovative Product for Complex Surgical Wounds

Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution

It didn't make as much money in the second quarter as investors were hoping.

Why Organogenesis Stock Is Tumbling Today

Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Ryan Zimmerman - BTIG Operator Good afternoon, ladies and gentlemen, and welcome to the Second Quarter 2022 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q2 2022 Results - Earnings Call Transcript

CANTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2022.

Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?

CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2022 financial results will be reported after the market closes on Tuesday, August 9th.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2022 Financial Results on August 9, 2022

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief Financial Officer Conference Call Participants Danielle Antalffy - SVB Leerink LLC Steven Lichtman - Oppenheimer & Co. Ryan Zimmerman - BTIG, LLC Matthew Miksic - Credit Suisse AG Operator Good afternoon, ladies and gentlemen, and welcome to the First Quarter 2022 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the Company's website for replay shortly.

News for Organogenesis Holdings Stock (ORGO)